Novalis Biotech is an early stage venture capital fund in life sciences.
Our investment ideas focus on the interaction between bio-informatics and life sciences. We strongly believe in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. Novalis focuses on capital light business models and platform technology.
Novalis was founded by Prof. Wim Van Criekinge and Jan Van den Berghe.
As an early stage private equity/venture capital fund, we are a dynamic and flexible player not restricting ourselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences.
We differentiate ourselves by high dynamism and flexibility to rapidly evolve our portfolio companies.